According to a new study just published in The Lancet, big pharma still spends little time on introducing new drugs for neglected diseases. Of 336 new chemical entities (NCEs) introduced between 2000 and 2011, only 1% were aimed at neglected diseases. It's not looking much better on the horizon either. According to this analysis, of the 150,000 ongoing clinical trials (are there really that many? wow), only 1% of those target neglected disease applications.
Generally speaking, neglected diseases fall heavily into the developing world and affect poverty stricken populations who have a tough time paying (or their governments in their behalf) for new treaments. While 13 members of Big Pharma (like GSK, J&J, Novartis, etc) announced more emphasis in this area to the tune of $785 M, that really pales next to the nearly $70 B spent on pharma R&D last year. Or about 1%. Hmmm, maybe we got something here. See Fierce Biotech.
Posted by Bruce Lehr Oct 25th 2013.